- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- News & Insights
- Events
- In the news
- Perspectives
- Press releases
- Research & publications
- Cell & Gene Pipeline Outlook
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Drug Approvals
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update: January 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Quarterly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals: July 2024
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- FDA Decisions Expected: April 2026
- FDA Decisions Expected: May 2026
- FDA Decisions Expected: June 2026
- FDA Decisions Expected: July 2026
- FDA Decisions Expected: August 2026
- FDA Decisions Expected: September 2026
- FDA Decisions Expected: October 2026
- GLP-1 Pipeline Update
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- GLP-1 Pipeline Update: May 2026
- GLP-1 Pipeline Update: August 2026
- Medicaid Trend Report
- Medical Pharmacy Trend Report
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- 2026 Medical Pharmacy Trend Report Part 1
- 2026 Medical Pharmacy Trend Report Part 2
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- Oncology Insights: April 2026
- Oncology Insights: May 2026
- Oncology Insights: June 2026
- Oncology Insights: July 2026
- Oncology Insights: August 2026
- Prime Therapeutics Report
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- Spring 2026 Prime Therapeutics Report
- Summer 2026 Prime Therapeutics Report
- Quarterly Drug Pipeline
- 2024-2025
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Quarterly Drug Pipeline: April 2026
- Quarterly Drug Pipeline: July 2026
- Research posters & abstracts
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Trending Topics & Drug Approvals: March 2026
- Trending Topics & Drug Approvals: April 2026
- Trending Topics & Drug Approvals: May 2026
- Trending Topics & Drug Approvals: June 2026
- Trending Topics & Drug Approvals: July 2026
- Trending Topics & Drug Approvals: August 2026
- White papers
- Stories
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- News & Insights
- Events
- In the news
- Perspectives
- Press releases
- Research & publications
- Cell & Gene Pipeline Outlook
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Drug Approvals
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update: January 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Quarterly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals: July 2024
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- FDA Decisions Expected: April 2026
- FDA Decisions Expected: May 2026
- FDA Decisions Expected: June 2026
- FDA Decisions Expected: July 2026
- FDA Decisions Expected: August 2026
- FDA Decisions Expected: September 2026
- FDA Decisions Expected: October 2026
- GLP-1 Pipeline Update
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- GLP-1 Pipeline Update: May 2026
- GLP-1 Pipeline Update: August 2026
- Medicaid Trend Report
- Medical Pharmacy Trend Report
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- 2026 Medical Pharmacy Trend Report Part 1
- 2026 Medical Pharmacy Trend Report Part 2
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- Oncology Insights: April 2026
- Oncology Insights: May 2026
- Oncology Insights: June 2026
- Oncology Insights: July 2026
- Oncology Insights: August 2026
- Prime Therapeutics Report
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- Spring 2026 Prime Therapeutics Report
- Summer 2026 Prime Therapeutics Report
- Quarterly Drug Pipeline
- 2024-2025
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Quarterly Drug Pipeline: April 2026
- Quarterly Drug Pipeline: July 2026
- Research posters & abstracts
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Trending Topics & Drug Approvals: March 2026
- Trending Topics & Drug Approvals: April 2026
- Trending Topics & Drug Approvals: May 2026
- Trending Topics & Drug Approvals: June 2026
- Trending Topics & Drug Approvals: July 2026
- Trending Topics & Drug Approvals: August 2026
- White papers
- Stories
- Compliance / Legal
Corporate social responsibility
At Prime Therapeutics (Prime), we strive to provide the care we would want for our loved ones. This includes our members, customers and people in our communities.
Building a culture where everyone can thrive
When a person feels safe to be who they are, they’re able to do their best work. At Prime, we practice radical welcomeness, which means we gladly, completely and earnestly receive colleagues of all backgrounds, races, ethnicities, abilities, gender identities, sexual orientations and religions.
Serving in our neighborhoods
Our passion to help goes beyond our work in health care. On any given day, Prime employees can be found serving others in the communities where we live and work.
PrimeCares
Our employees donate, volunteer and participate in events through our community giving program, PrimeCares.
Prime Together Foundation
Born out of employees’ passion, the Prime Together Foundation helps address inequality and injustice.